Filed
by a Party other than the Registrant
|
o
|
o
|
Preliminary
Proxy Statement
|
o
|
Confidential,
for Use of the Commission Only (as permitted by Rule 14a-6(e)
(2))
|
x
|
Definitive
Proxy Statement
|
o
|
Definitive
Additional Materials
|
o
|
Soliciting
Material Pursuant to § 240.14a-12
|
x
|
No
fee required.
|
o
|
Fee
computed on table below per Exchange Act Rules 14a-6(i)(1) and
0-11.
|
o
|
Fee
paid previously with preliminary materials.
|
o
|
Check
box if any part of the fee is offset as provided by Exchange Act
Rule
0-11(a)(2) and identify the filing for which the offsetting fee
was paid
previously. Identify the previous filing by registration statement
number,
or the Form or Schedule and the date of its
filing.
|
1. |
Election
of three directors, constituting the class of directors to be elected
for
a three-year term expiring in 2009.
|
2. |
Ratification
of the Audit Committee's
selection of PricewaterhouseCoopers LLP as the Company's
independent auditors for 2006.
|
3. |
A
stockholder proposal regarding the vote standard for director elections,
if presented by its proponent at the
meeting.
|
4. |
Such
other business as may properly be brought before the meeting and
any
adjournment thereof.
|
[PHOTO]
|
Peter
J. Manning
|
Mr.
Manning, age 67, has been a director of the Company since May 2003.
He
served as vice chairman, Strategic Business Development of FleetBoston
Financial Corporation from October 1999 to February 2003 when he
retired.
From January 1993 to October 1999, Mr. Manning served as executive
director, Mergers & Acquisitions of BankBoston Corporation, prior to
its acquisition by FleetBoston Financial. From 1990 to 1993, he
served as
executive vice president and chief financial officer of BankBoston
Corporation. Mr. Manning is also a director of Safety Insurance
Group
Inc.
|
[PHOTO]
|
Jim
P. Manzi
|
Mr.
Manzi, age 54, has been a director of the Company since May 2000
and
Chairman of the Board since January 2004. He has been the chairman
of
Stonegate Capital, a firm he formed to manage private equity investment
activities in technology startup ventures, primarily related to
the
Internet, since 1995. From 1984 until 1995, he served as the chairman,
president and chief executive officer of Lotus Development Corporation,
a
software manufacturer that was acquired by IBM Corporation in 1995.
|
[PHOTO]
|
Elaine
S. Ullian
|
Ullian,
age 58, has been a director of the Company since July 2001. She
has been
the president
and chief executive officer of Boston Medical Center, a 550-bed
academic
medical center affiliated with Boston University, since July 1996.
Ms.
Ullian is also a director of Vertex Pharmaceuticals, Inc. and Valeant
Pharmaceuticals
International.
|
[PHOTO]
|
John
L. LaMattina
|
Dr.
LaMattina,
age 56, has been a director of the Company since January 2002.
He has been
senior vice president, Pfizer Inc., a pharmaceutical company, and
president, Pfizer Global Research and Development, since October
2003.
From April 2001 to October 2003, he served as vice president, Pfizer
Inc.;
executive vice president, Pfizer Global Research and Development;
and
president, Pfizer Worldwide Research and Technology Alliances.
From August
1999 to April 2001, Dr. LaMattina served as senior vice president,
Worldwide Discovery, Pfizer Central Research. From 1977 until August
1999,
he held various positions of increasing responsibility in research
and
development at Pfizer Inc.
|
[PHOTO]
|
Michael
E. Porter
|
Dr.
Porter, age 58, has been a director of the Company since July 2001.
He has
been the Bishop William Lawrence University Professor at the Harvard
Business School since December 2000 and C. Roland Christensen Professor
of
Business Administration since 1990. Dr. Porter is a leading authority
on
competitive strategy and international competitiveness. Dr. Porter
is also
a director of Parametric Technology Corporation and a supervisor
of Taiwan
Semiconductor Manufacturing Company
Limited.
|
[PHOTO]
|
Marijn
E. Dekkers
|
Mr.
Dekkers, age 48, has been a director since July 2000 and the Company's
president and chief executive officer since November 2002. He served
as
the Company's president and chief operating officer from July 2000
to
November 2002. Prior to joining the Company, Mr. Dekkers held various
positions of increasing responsibility at Honeywell International
Inc.
(formerly AlliedSignal Inc.) and General Electric
Company.
|
[PHOTO]
|
Robert
A. McCabe
|
Mr.
McCabe, age 71, has been a director of the Company since 1962.
He has been
the chairman of Pilot Capital Corporation, an entity engaged in
private
investments, since 1998 and he served as its president from 1987
to 1998.
Mr. McCabe is also a director of Church & Dwight Co., Inc.
|
[PHOTO]
|
Robert
W. O’Leary
|
Mr.
O'Leary, age 62, has been a director of the Company since June
1998. He
has been the chairman of the board of directors of Valeant Pharmaceuticals
International, a research-based global pharmaceutical company,
since June
2002. From June 2002 to January 2005, Mr. O’Leary also served as the chief
executive officer of Valeant. From January 2001 to June 2002, he
served as
the chairman and chief executive officer of The Sagamore Group,
a firm
specializing in change management situations. Mr. O'Leary served
as the
president and chief executive officer of PacificCare Health Systems
Inc.,
a managed health services company, from July 2000 to October 2000.
From
January 1996 until June 2000, he served as the chairman of Premier
Inc., a
strategic alliance of not-for-profit health care and hospital systems.
From January 1996 until September 1998 he also served as chief
executive
officer of Premier Inc. Mr. O'Leary is also a director of Smiths
Group PLC
and Viasys Healthcare Inc.
|
Name(1)
|
Shares
(2)
|
Options
Exercisable
within
60 Days (3)
|
Deferred
Stock
Units
(4)
|
Total
|
Percent
of
Shares
Beneficially
Owned
|
|||||||||||
Dodge
& Cox(5) . . . . . . . . . . . . . . . .
|
19,582,357
|
|
-
-
|
-
-
|
19,582,357
|
12.00
|
%
|
|||||||||
FMR
Corp.(6) . . . . . . . . . . . . . . . . . .
|
12,475,722
|
-
-
|
-
-
|
12,475,722
|
7.64
|
%
|
||||||||||
Guy
Broadbent . . . . . . . . . . . . . . . .
|
20,005
|
337,479
|
-
-
|
357,484
|
*
|
|||||||||||
Marc
N. Casper . . . . . . . . . . . . . . . .
|
27,207
|
346,333
|
20,000
|
393,540
|
*
|
|||||||||||
Marijn
E. Dekkers . . . . . . . . . . . . . .
|
118,418
|
1,900,646
|
100,000
|
2,119,064
|
1.28
|
%
|
||||||||||
Seth
H. Hoogasian . . . . . . . . . . . . . .
|
30,685
|
170,147
|
-
-
|
200,832
|
*
|
|||||||||||
John
L. LaMattina . . . . . . . . . . . . . .
|
3,000
|
32,500
|
-
-
|
35,500
|
*
|
|||||||||||
Peter
J. Manning . . . . . . . . . . . . . . .
|
3,000
|
12,500
|
-
-
|
15,500
|
*
|
|||||||||||
Jim
P. Manzi . . . . . . . . . . . . . . . . . .
|
26,946
|
176,000
|
8,279
|
211,225
|
*
|
|||||||||||
Robert
A. McCabe . . . . . . . . . . . . . .
|
32,558
|
18,500
|
40,384
|
91,442
|
*
|
|||||||||||
Robert
W. O’Leary . . . . . . . . . . . . . .
|
1,000
|
25,795
|
12,285
|
39,080
|
*
|
|||||||||||
Michael
E. Porter. . . . . . . . . . . . . . .
|
4,500
|
35,944
|
-
-
|
40,444
|
*
|
|||||||||||
Elaine
S. Ullian. . . . . . . . . . . . . . . . .
|
500
|
35,944
|
11,597
|
48,041
|
*
|
|||||||||||
Peter
M. Wilver . . . . . . . . . . . . . . . . .
|
13,279
|
227,738
|
-
-
|
241,017
|
*
|
|||||||||||
All
directors and current executive officers as a group
(14 persons) . . . .
|
297,151
|
3,524,617
|
192,545
|
4,014,313
|
2.40
|
%
|
|
|
|
|
Annual
Compensation
|
|
Long
Term Compensation
|
|
|
|
||||||||||
Name
and
Principal
Position
|
|
Fiscal
Year
|
|
Salary
|
|
Bonus
|
|
Restricted
Stock
Awards
|
Securities
Underlying
Options
|
|
All
Other
Compensation
(1)(2)
|
|
|||||||
Marijn
E. Dekkers
|
|
|
2005
|
|
|
$1,000,000
|
|
|
$1,339,500
|
|
|
$2,884,100
|
(3)
|
|
438,000
|
|
|
$133,939
|
|
President
and Chief
|
|
|
2004
|
|
|
$997,692
|
|
|
$1,107,000
|
|
|
$128,050
|
(4)
|
|
--
|
|
|
$209,211
|
|
Executive
Officer
|
|
|
2003
|
|
|
$794,872
|
|
|
$820,800
|
|
|
--
|
|
|
--
|
|
|
$335,455
|
|
Marc
N. Casper
|
|
|
2005
|
|
|
$553,558
|
|
|
$634,500
|
|
|
--
|
|
|
265,000
|
|
|
$45,397
|
|
Senior
Vice President
|
|
|
2004
|
|
|
$425,000
|
|
|
$359,550
|
|
|
--
|
|
|
--
|
|
|
$56,824
|
|
|
|
|
2003
|
|
|
$359,039
|
|
|
$287,500
|
|
|
$1,211,700
|
(5)
|
|
--
|
|
|
$67,622
|
|
Guy
Broadbent
|
|
|
2005
|
|
|
$335,004
|
|
|
$420,000
|
|
|
--
|
|
|
125,000
|
|
|
$42,653
|
|
President,
Laboratory
|
|
|
2004
|
|
|
$316,868
|
|
|
$191,580
|
|
|
--
|
|
|
--
|
|
|
$250,619
|
(6)
|
Equipment
|
|
|
2003
|
|
|
$305,513
|
|
|
$212,040
|
|
|
--
|
|
|
--
|
|
|
$74,605
|
|
Seth
H. Hoogasian
|
|
|
2005
|
|
|
$363,000
|
|
|
$307,098
|
|
|
--
|
|
|
125,000
|
|
|
$38,473
|
|
General
Counsel
|
|
|
2004
|
|
|
$354,369
|
|
|
$223,245
|
|
|
$304,900
|
(7)
|
|
--
|
|
|
$37,846
|
|
|
|
|
2003
|
|
|
$324,435
|
|
|
$188,100
|
|
|
--
|
|
|
--
|
|
|
$118,623
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peter
M. Wilver
|
|
|
2005
|
|
|
$359,227
|
|
|
$307,796
|
|
|
--
|
|
|
125,000
|
|
|
$29,960
|
|
Chief
Financial Officer
|
|
|
2004
|
|
|
$316,853
|
(8)
|
|
$196,890
|
(8)
|
|
$277,000
|
(9)
|
|
125,000
|
|
|
$29,735
|
|
|
|
|
2003
|
|
|
$266,237
|
(10)
|
|
$148,200
|
(10)
|
|
--
|
|
|
--
|
|
|
$31,712
|
|
Option
Grants 2005
|
|||||||
Individual
Grants
|
|||||||
Name
|
Number
of Securities Underlying Options (1)
|
Percent
of Total Options Granted to Employees in Fiscal
Year
|
Exercise
Price Per
Share
|
Expiration
Date
|
Potential
Realizable Value at Assumed Annual Rates of Stock Price Appreciation
for
Option Term (2)
|
||
5%
|
10%
|
||||||
Marijn
E. Dekkers
|
438,000
|
12.67%
|
$27.40
|
2/25/2012
|
$4,885,710
|
$11,385,722
|
|
Marc
N. Casper
|
265,000
|
7.66%
|
$27.40
|
2/25/2012
|
$2,955,970
|
$6,888,622
|
|
Guy
Broadbent
|
125,000
|
3.62%
|
$27.40
|
2/25/2012
|
$1,394,320
|
$3,249,350
|
|
Seth
H. Hoogasian
|
125,000
|
3.62%
|
$27.40
|
2/25/2012
|
$1,394,320
|
$3,249,350
|
|
Peter
M. Wilver
|
125,000
|
3.62%
|
$27.40
|
2/25/2012
|
$1,394,320
|
$3,249,350
|
Aggregated
Option Exercises In Fiscal 2005 and Fiscal 2005 Year-End Option
Values
|
|||||||
Name
|
Shares
Acquired
on
Exercise
|
Value
Realized
(1)
|
Number
of
Securities
Underlying
Unexercised
Options
at Fiscal
Year-End
(Exercisable/
Unexercisable) (2)
|
Value
of
Unexercised
In-the-Money
Options
at Fiscal
Year-End
(Exercisable/
Unexercisable)
(2)
|
|||
Marijn
E. Dekkers
|
-
|
-
|
1,754,646/
|
960,600
|
$17,606,090/
|
$6,662,136
|
|
Marc
N. Casper
|
-
|
-
|
258,000/
|
332,000
|
$2,133,930/
|
$1,424,270
|
|
Guy
Broadbent
|
10,000
|
$78,600
|
310,813/
|
192,000
|
$2,471,467/
|
$1,042,070
|
|
Seth
H. Hoogasian
|
105,556
|
$1,406,200
|
128,481/
|
192,000
|
$1,215,345/
|
$1,042,070
|
|
Peter
M. Wilver
|
-
|
-
|
186,072/
|
275,334
|
$1,297,112/
|
$1,042,070
|
Plan
Category
|
(a)
Number
of securities to be issued upon exercise of outstanding options,
warrants
and rights
|
(b)
Weighted
average exercise price of outstanding options, warrants
and rights
|
(c)
Number
of securities remaining available for future issuance under equity
compensation plans (excluding securities
reflected
in column (a))(1)
|
Equity
Compensation Plans Approved By Security Holders(2)(3)
|
9,203,178
|
$22.96
|
11,670,782
|
Equity
Compensation Plans Not Approved By Security Holders(4)(5)
|
2,380,707
|
$21.56
|
41,774
|
Total
|
11,583,885
|
$22.67
|
11,712,556
|
|
12/29/00
|
12/28/01
|
12/27/02
|
12/31/03
|
12/31/04
|
12/31/05
|
THERMO
ELECTRON CORPORATION
|
100.00
|
105.80
|
89.39
|
112.64
|
134.94
|
134.67
|
S&P
500
|
100.00
|
88.12
|
68.64
|
88.33
|
97.94
|
102.75
|
S&P
500 HEALTH CARE EQUIPMENT
|
100.00
|
94.93
|
82.91
|
109.49
|
123.31
|
123.38
|
Fiscal
2005
|
Fiscal
2004
|
||
Audit
Fees
|
$7,509,000
|
(1)
|
$9,182,000
|
Audit-Related
Fees
|
115,000
|
149,000
|
|
Tax
Fees
|
3,000
|
52,000
|
|
All
Other Fees
|
--
|
--
|
|
Total
Fees
|
$7,627,000
|
$9,383,000
|
A. |
PURPOSE
|
· |
the
integrity of the Company’s financial
statements;
|
· |
the
Company’s compliance with legal and regulatory
requirements;
|
· |
the
independent auditor’s qualifications and independence;
and
|
· |
the
performance of the Company’s internal audit function and independent
auditors;
|
B.
|
STRUCTURE
AND MEMBERSHIP
|
1. |
Number.
The Audit Committee shall consist of at least three members of the
Board
of Directors.
|
2. |
Independence.
Except as otherwise permitted by the applicable rules of the New
York
Stock Exchange (“NYSE”) and/or the SEC, each member of the Audit Committee
shall be independent as defined by such rules.
|
3. |
Financial
Literacy.
Each member of the Audit Committee must be financially literate,
as such
qualification is interpreted by the Board of Directors in its business
judgment, or must become financially literate within a reasonable
period
of time after his or her appointment to the Audit Committee. At least
one
member of the Audit Committee must have accounting or related financial
management expertise, as the Board of Directors interprets such
qualification in its business judgment. Unless otherwise determined
by the
Board of Directors (in which case disclosure of such determination
shall
be made in the Company’s annual report filed with the SEC), at least one
member of the Audit Committee shall be an “audit committee financial
expert” (as defined by applicable SEC
rules).
|
4. |
Chair.
Unless the Board of Directors elects a Chair of the Audit Committee,
the
Audit Committee shall elect a Chair by majority vote.
|
5. |
Compensation.
The compensation of Audit Committee members shall be as determined
by the
Board of Directors. No member of the Audit Committee may receive,
directly
or indirectly, any consulting, advisory or other compensatory fee
from the
Company or any of its subsidiaries, other than fees paid in his or
her
capacity as a member of the Board of Directors or a committee of
the Board
of Directors.
|
6. |
Selection
and Removal.
Members of the Audit Committee shall be appointed by the Board of
Directors, upon the recommendation of the Nominating and Corporate
Governance Committee. Unless otherwise determined by the Board of
Directors (in which case disclosure of such determination shall be
made in
the Company’s annual proxy statement), no member of the Audit Committee
may serve on the audit committee of more than two other public companies.
The Board of Directors may remove members of the Audit Committee
from such
committee, with or without cause.
|
C.
|
AUTHORITY
AND RESPONSIBILITIES
|
1. |
Selection.
The Audit Committee shall be directly responsible for appointing,
evaluating, retaining and, when necessary, terminating the engagement
of
the independent auditor.
|
2. |
Independence.
At least annually, the Audit Committee shall assess the independent
auditor’s independence. In connection with this assessment, the Audit
Committee shall obtain and review a report by the independent auditor
describing all relationships between the independent auditor and
the
Company, including the disclosures required by Independence Standards
Board Standard No. 1. The Audit Committee shall engage in an active
dialogue with the independent auditor concerning any disclosed
relationships or services that might impact the objectivity and
independence of the auditor.
|
3. |
Quality-Control
Report.
At least annually, the Audit Committee shall obtain and review a
report by
the independent auditor describing:
|
· |
the
firm’s internal quality-control
procedures;
|
· |
any
material issues raised by the most recent internal quality-control
review,
or peer review, of the firm, or by any inquiry or investigation by
governmental or professional authorities, within the preceding five
years,
respecting one or more independent audits carried out by the firm,
and any
steps taken to deal with any such
issues.
|
4.
|
Compensation.
The Audit Committee shall be directly responsible for setting the
compensation of the independent auditor. The Audit Committee is empowered,
without further action by the Board of Directors, to cause the Company
to
pay the compensation of the independent auditor established by the
Audit
Committee.
|
5.
|
Preapproval
of Services.
The Audit Committee shall preapprove all audit services to be provided
to
the Company, whether provided by the principal auditor or other firms,
and
all other services (review, attest and non-audit) to be provided
to the
Company by the independent auditor; provided,
however,
that de minimis non-audit services may instead be approved in accordance
with applicable NYSE and SEC rules. To the extent permitted by applicable
NYSE and SEC rules and consistent with the requirements of such rules,
the
Audit Committee may delegate to one or more members of the Audit
Committee
the authority to grant approvals of permitted non-audit services
required
to be approved by the Audit Committee under NYSE and SEC rules;
provided,
however,
that any approvals granted under such delegation of authority shall
be
presented to the Audit Committee at the next regularly scheduled
meeting
thereof.
|
6.
|
Oversight.
The independent auditor shall report directly to the Audit Committee,
and
the Audit Committee shall be directly responsible for oversight of
the
work of the independent auditor, including resolution of disagreements
between Company management and the independent auditor regarding
financial
reporting, for the purpose of preparing or issuing an audit report
or
performing other audit, review or attest services for the Company.
In
connection with its oversight role, the Audit Committee shall, from
time
to time as appropriate:
|
· |
receive
and consider the reports required to be made by the independent auditor
regarding:
|
-
|
critical
accounting policies and practices;
|
-
|
alternative
treatments within generally accepted accounting principles for
policies
and practices related to material items that have been discussed
with
Company management, including ramifications of the use of such
alternative
disclosures and treatments, and the treatment preferred by the
independent
auditor; and
|
-
|
other
material written communications between the independent auditor
and
Company management.
|
· |
review
with the independent auditor:
|
-
|
any
audit problems or difficulties the independent auditor encountered
in the
course of the audit work and management’s response, including any
restrictions on the scope of the independent auditor’s activities or on
access to requested information and any significant disagreements
with
management;
|
-
|
any (i)
significant matters regarding internal controls over financial
reporting
that have come to the independent auditor’s attention during the
conduct of its audit, review, or attest services and any special
audit
steps adopted in light thereof and (ii) major issues as to the
adequacy of the Company's internal controls over financial
reporting that have come to the Audit Committee's
attention;
|
-
|
analyses
prepared by management and/or the independent auditor setting
forth
significant financial reporting issues and judgments made in
connection
with the preparation of the financial statements, including analyses
of
the effects of alternative GAAP methods on the financial statements;
|
-
|
the
effect of regulatory and accounting initiatives, as well as off-balance
sheet structures, on the financial statements of the Company;
and
|
-
|
any
accounting adjustments that were noted or proposed by the auditor
but were
“passed” as immaterial or
otherwise.
|
7.
|
Review
and Discussion.
The Audit Committee shall meet to review and discuss with the Company's
management and independent auditor the Company's audited financial
statements, including reviewing the Company’s specific disclosures under
“Management’s Discussion and Analysis of Financial Condition and Results
of Operations,” and the matters about which Statement on Auditing
Standards No. 61 (Codification of Statements on Auditing Standards,
AU
§380) requires discussion.
|
8.
|
Recommendation
to Board Regarding Financial Statements.
The Audit Committee shall consider whether it will recommend to the
Board
of Directors that the Company's audited financial statements be included
in the Company's Annual Report on Form
10-K.
|
9.
|
Audit
Committee Report.
The Audit Committee shall prepare an annual committee report for
inclusion
where necessary in the proxy statement of the Company relating to
its
annual meeting of security holders.
|
10.
|
Independent
Auditor Review of Interim Financial Statements.
The Audit Committee shall direct the independent auditor to use its
best
efforts to perform all reviews of interim financial information prior
to
disclosure by the Company of such information and to discuss promptly
with
the Audit Committee and the Chief Financial Officer any matters identified
in connection with the auditor's review of interim financial information
which are required to be discussed by applicable auditing standards.
The
Audit Committee shall direct management to advise the Audit Committee
in
the event that the Company proposes to disclose interim financial
information prior to completion of the independent auditor’s review of
interim financial information.
|
11.
|
Earnings
Release and Other Financial Information.
The Audit Committee shall discuss generally the types of information
to be
disclosed in the Company’s earnings press releases, as well as in
financial information and earnings guidance provided to analysts
and
rating agencies.
|
12.
|
Quarterly
Financial Statements.
The
Audit Committee shall meet to review and discuss with the Company's
management and independent auditor the Company's quarterly financial
statements, including reviewing the Company’s specific disclosures under
“Management’s Discussion and Analysis of Financial Condition and Results
of Operations.”
|
13.
|
Oversight.
The Audit Committee shall coordinate the Board of Directors' oversight
of
the Company’s internal controls over financial reporting, the Company’s
disclosure controls and procedures and the Company’s code of business
conduct and ethics. The Audit Committee shall receive and review
the
reports of the CEO and CFO required by Section 302 of the Sarbanes-Oxley
Act of 2002 (and the applicable rules thereunder) and Rule 13a-14
of the
Exchange Act.
|
14.
|
Internal
Audit Function.
The Audit Committee shall coordinate the Board of Directors' oversight
of
the Company’s internal audit function, including its performance. The
Audit Committee shall (i) discuss with the independent auditor and
management the internal audit function’s responsibilities, budget and
staffing and any recommended changes in the planned internal audits;
and
(ii) discuss with management (including the Company's internal auditor)
management's assessments of the Company's system of internal
controls.
|
15.
|
Risk
Management.
The Audit Committee shall discuss with management (including the
Company's
internal auditor) the Company’s policies with respect to risk assessment
and risk management, including insurance, and other guidelines and
policies to govern the process by which the Company’s exposure to risk is
handled. The Audit Committee shall discuss with management the Company’s
major financial risk exposures and the steps management has taken
to
monitor and control such exposures.
|
16.
|
Hiring
Policies.
The Audit Committee shall establish policies regarding the hiring
of
employees or former employees of the Company’s independent
auditors.
|
17.
|
Procedures
for Complaints.
The Audit Committee shall establish procedures for (i) the receipt,
retention and treatment of complaints received by the Company regarding
accounting, internal accounting controls or auditing matters; and
(ii) the
confidential, anonymous submission by employees of the Company of
concerns
regarding questionable accounting or auditing
matters.
|
18.
|
Additional
Powers.
The Audit Committee shall have such other duties as may be delegated
from
time to time by the Board of
Directors.
|
1.
|
Meetings.
The Audit Committee shall meet as often as it deems necessary in
order to
perform its responsibilities. The Audit Committee may also act
by
unanimous written consent in lieu of a meeting. The Audit Committee
shall
periodically meet separately with: (i) the independent auditor;
(ii) Company management and (iii) the Company’s internal
auditors. The Audit Committee shall keep such records of its meetings
as
it shall deem appropriate.
|
2.
|
Subcommittees.
The Audit Committee may form and delegate authority to one or more
subcommittees (including a subcommittee consisting of a single member),
as
it deems appropriate from time to time under the circumstances. Any
decision of a subcommittee to pre-approve audit, review, attest or
non-audit services shall be presented to the full Audit Committee
at its
next scheduled meeting.
|
3.
|
Reports
to Board.
The Audit Committee shall report regularly to the Board of
Directors.
|
4.
|
Charter.
At least annually, the Audit Committee shall review and reassess
the
adequacy of this Charter and recommend any proposed changes to the
Board
of Directors for approval.
|
5.
|
Written
Affirmation to NYSE.
On an annual basis, no later than one month after the Annual Meeting
of
Stockholders, and after each change in the composition of the Audit
Committee, the Audit Committee shall direct the Company to prepare
and
provide to the NYSE such written confirmations regarding the membership
and operation of the Audit Committee as the NYSE rules
require.
|
6.
|
Independent
Advisors.
The Audit Committee is authorized, without further action by the
Board of
Directors, to engage such independent legal, accounting and other
advisors
as it deems necessary or appropriate to carry out its responsibilities.
Such independent advisors may be the regular advisors to the Company.
The
Audit Committee is empowered, without further action by the Board
of
Directors, to cause the Company to pay the compensation of such advisors
as established by the Audit
Committee.
|
7.
|
Investigations.
The Audit Committee shall have the authority to conduct or authorize
investigations into any matters within the scope of its responsibilities
as it shall deem appropriate, including the authority to request
any
officer, employee or advisor of the Company to meet with the Audit
Committee or any advisors engaged by the Audit
Committee.
|
8.
|
Funding.
The Audit Committee is empowered, without further action by the Board
of
Directors, to cause the Company to pay the ordinary administrative
expenses of the Audit Committee that are necessary or appropriate
in
carrying out its duties.
|
9.
|
Annual
Self-Evaluation.
At least annually, the Audit Committee shall evaluate its own
performance.
|
Internet
https://
www.voteproxy.com
|
Telephone
1-800-PROXIES
|
-
Go to the website address listed above.
|
-
Use any touch-tone telephone.
|
-
Have your proxy card ready.
|
-
Have your proxy card ready.
|
-
Follow the instructions that appear on your computer
screen.
|
-
Follow the recorded instructions.
|
Your
Internet or telephone vote authorizes the named proxies to vote
your
shares in the same manner as if you marked, signed and returned
your proxy
card. You need not mail back your proxy card if you have voted
by Internet
or telephone.
1-800-PROXIES
CALL
TOLL-FREE TO VOTE
www.voteproxy.com
|
1.
|
Election
of Directors.
|
Nominees:
|
o
|
(01)
Peter J. Manning
|
o
|
(02)
Jim P. Manzi
|
|
|
o
|
(03)
Elaine S. Ullian
|
FOR
ALL NOMINEES
|
o
|
WITHHELD
FROM ALL NOMINEES
|
o
|
FOR
ALL EXCEPT (See
instructions below)
|
o
|
INSTRUCTIONS:
|
To
withhold authority for an individual nominee(s), mark “FOR ALL EXCEPT” and
fill in the circle next to each nominee you wish to withhold authority
for.
|
2.
|
Ratification
of Selection of Independent
Auditors.
|
FOR
|
o
|
AGAINST
|
o
|
ABSTAIN
|
o
|
3.
|
Stockholder
Proposal Regarding the Vote Standard for Director
Elections.
|
FOR
|
o
|
AGAINST
|
o
|
ABSTAIN
|
o
|
4.
|
In
their discretion on such other matters as may properly come before
the
meeting.
|
SIGNATURE(S)
________________________________
|
DATE
__________________________________
|